Illumina · 7 hours ago
Director, Product Management, Low Throughput NGS Systems
Illumina is a company dedicated to expanding access to genomic technology for better health equity worldwide. The Director of Product Management for Low Throughput NGS Systems will oversee the full product lifecycle for MiSeq and related systems, collaborating with various teams to drive strategic planning and product management responsibilities.
BiotechnologyGeneticsHealth CareMedical
Responsibilities
Leads a team that assesses market opportunities & trends and customer needs for MiSeq and LT NGS Systems across RUO and Dx. This strategy includes the assessment and tracking of the technology and competitive landscape in partnership with customer and field marketing, commercial leadership, and the sales teams
Develops strategic plan for investment and revenue growth in the LT NGS systems, focused on targeted customer segments
Ideal candidate would have experience across the RUO to Dx system continuum bringing Dx systems to market
Leads and manages the product management team regarding Product Lifecycle activities including new product proposals, development related activities, product launch readiness & technical content for new product introductions (NPI’s), product conversions and/or end of life (EOL) activities for the library preparation and array product portfolio
The team also acts as a primary interface with the operation team to manage portfolio forecasting, inventory, back orders, and external communications regarding product issues, toward optimizing global asset utilization across regions and markets
Drives lifecycle management activities to support revenue growth goals across markets
Orchestrates fluid EOL strategy to optimize revenue attainment
Designs / implements effective forecasting models in partnership with key stakeholders (quarterly, annual, and 2-5 Year) with granularity at the product family, market segment and regional level
Sets high level pricing strategy in coordination with Pricing COE including regional drivers
Sets and delivers against product revenue and profitability goals
Acts as an internal and external evangelist toward shaping corporate and marketing strategy
Interfaces between ops and marketing/sales leadership
Provides input (e.g., product, service needs) to R&D and technical platform roadmap
Partners with product marketing to provide guidance, input, and sign-off for GTM strategy and plans
Serve as the single owner for NPI commercial success across all commercial functions and is the primary point of contact for leadership and is accountable for year 1 NPI revenue
Develops content and communicates with global segment marketing
Performs competitive differentiation and analysis of performance claims
Qualification
Required
Strong background in Genomics and Next Generation Sequencing (NGS) technologies across the Dx continuum
Ability and experience developing holistic and comprehensive business strategies managing both long-term strategy and executional detail
Experience managing diverse, multi-faceted teams
Ability to influence diverse stakeholder groups within a global, matrixed organization
Excellent interpersonal, verbal, and written communication skills
Sound business judgment and discretion for managing product portfolios; ability to develop and execute against dynamic timelines
Organizational capabilities to leverage organizations to proactively execute against business goals
BS or MS in a biological discipline with a strong marketing and business development background
Typically requires 18 years work experience in Life Sciences and/or Clinical field with 5+ years in Genomics preferred
Preferred
Advanced degree(s) preferred
Typically has 10+ years of applicable management experience
Benefits
Access to genomics sequencing
Family planning
Health/dental/vision
Retirement benefits
Paid time off
Company
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Funding
Current Stage
Public CompanyTotal Funding
$1.28BKey Investors
Bank of America
2024-09-06Post Ipo Debt· $500M
2023-01-04Post Ipo Debt· $750M
2000-07-28IPO
Leadership Team
Recent News
2026-01-14
thefly.com
2026-01-14
Company data provided by crunchbase